Literature DB >> 19567818

An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells.

Joseph Kwong1, Hagen Kulbe, Donald Wong, Probir Chakravarty, Fran Balkwill.   

Abstract

The chemokine receptor CXCR4 is expressed by malignant cells in ovarian cancer and is implicated in their growth and spread. We report here a unique mechanism of action of a small peptide antagonist of CXCR4 on ovarian cancer cells: induction of cell death by mitotic catastrophe. CTCE-9908 inhibited ovarian cancer cell migration to CXCL12, but on longer incubation, caused cell death in CXCR4-positive cells. CTCE-9908 did not cause apoptosis or cellular senescence, but induced multinucleation, G(2)-M arrest, and abnormal mitosis in ovarian cancer cells. This suggests that cell death was caused by mitotic catastrophe. Using microarray and Western blot analysis, we showed that CTCE-9908 deregulated DNA damage checkpoint proteins and spindle assembly checkpoint proteins at G(2)-M phases of the cell cycle. Combination treatment of CTCE-9908 and the drug paclitaxel led to an additive cytotoxicity that also involved mitotic catastrophe. We conclude that CTCE-9908 has a unique mechanism of action in ovarian cancer cells that seems to be CXCR4 specific.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19567818     DOI: 10.1158/1535-7163.MCT-08-0966

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  25 in total

Review 1.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 2.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 3.  Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

4.  A switch between cytoprotective and cytotoxic autophagy in the radiosensitization of breast tumor cells by chloroquine and vitamin D.

Authors:  Eden N Wilson; Molly L Bristol; Xu Di; William A Maltese; Kristen Koterba; Matthew J Beckman; David A Gewirtz
Journal:  Horm Cancer       Date:  2011-10       Impact factor: 3.869

Review 5.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.

Authors:  F Guo; Y Wang; J Liu; S C Mok; F Xue; W Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 6.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

7.  Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in a breast cancer cell line.

Authors:  Xiao-Ping Chen; Lin-Lin Qian; Hong Jiang; Jiang-Hua Chen
Journal:  Int J Clin Oncol       Date:  2011-04-01       Impact factor: 3.402

8.  Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.

Authors:  Balraj Singh; Kendra R Cook; Cecilia Martin; Eugene H Huang; Kailash Mosalpuria; Savitri Krishnamurthy; Massimo Cristofanilli; Anthony Lucci
Journal:  Clin Exp Metastasis       Date:  2010-03-13       Impact factor: 5.150

9.  Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610.

Authors:  Meena Okera; Kyoungwha Bae; Eric Bernstein; Liang Cheng; Colleen Lawton; Harvey Wolkov; Alan Pollack; Adam Dicker; Howard Sandler; Christopher J Sweeney
Journal:  BJU Int       Date:  2010-12-13       Impact factor: 5.588

10.  Overexpression of the dynein light chain km23-1 in human ovarian carcinoma cells inhibits tumor formation in vivo and causes mitotic delay at prometaphase/metaphase.

Authors:  Nageswara R Pulipati; Qunyan Jin; Xin Liu; Baodong Sun; Manoj K Pandey; Jonathan P Huber; Wei Ding; Kathleen M Mulder
Journal:  Int J Cancer       Date:  2011-04-25       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.